Literature DB >> 7285274

Prognostic factors in metastatic breast cancer.

M F Fey, K W Brunner, R W Sonntag.   

Abstract

Modern polychemotherapy has decisively changed the spontaneous course and median survival in metastatic stages of breast cancer. The prognosis for patients with the rather unfavorable type of visceral metastatic spread is definitely better now than 10 years ago. The influence of modern polychemotherapy on the survival and course of cases with mainly osseous metastases, however, is more limited. It seems that, in contrast to hormonal therapy, modern polychemotherapy alters the course of more aggressive types of metastases with a poor prognosis into a more favorable form of disease.

Entities:  

Mesh：

Year:  1981        PMID： 7285274

Source DB:  PubMed          Journal:  Cancer Clin Trials        ISSN： 0190-1206


  9 in total

Review 1.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

2.  Newly recognized syndrome in the neck.

Authors:  R Amin
Journal:  J R Soc Med       Date:  1983-01       Impact factor: 5.344

3.  Plasma TGF-beta1-related survival of postmenopausal metastatic breast cancer patients.

Authors:  D Nikolić-Vukosavljević; N Todorović-Raković; M Demajo; V Ivanović; B Nesković; M Markićević; Z Nesković-Konstantinović
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.

Authors:  R V Smalley; J Lefante; A Bartolucci; J Carpenter; C Vogel; S Krauss
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

5.  Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy.

Authors:  J F Robertson; A R Dixon; R I Nicholson; I O Ellis; C W Elston; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

6.  Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research.

Authors:  F Cavalli; M Beer; G Martz; W F Jungi; P Alberto; J P Obrecht; B Mermillod; K W Brunner
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-01

7.  Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading.

Authors:  G Blanco; K Holli; M Heikkinen; O P Kallioniemi; P Taskinen
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

8.  The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.

Authors:  M J Lind; L Gumbrell; B M Cantwell; M J Millward; D Simmonds; M Proctor; F Chapman; E McCann; I Middleton; A H Calvert
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

9.  Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer.

Authors:  Carlos H Barcenas; Juhee Song; Rashmi K Murthy; Akshara S Raghavendra; Yisheng Li; Limin Hsu; Robert W Carlson; Debu Tripathy; Gabriel N Hortobagyi
Journal:  JCO Clin Cancer Inform       Date:  2021-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.